HighTower Advisors
ALGS icon

HighTower Advisors’s Aligos Therapeutics ALGS Stock Holding History

HighTower Advisors’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-400
Closed -$4K – 3739
2024
Q2 		$4K Buy
+400
New +$7.03K ﹤0.01% 3496

Other funds holding ALGS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HighTower Advisors's ALGS Position: Q3 2024 in Review

HighTower Advisors sold out of Aligos Therapeutics (ALGS) in Q3 2024, closing a stake of 400 shares — an estimated $4K sold.

HighTower Advisors first reported a position in ALGS in Q2 2024 and held it in 1 quarter. The position peaked at $4K in Q2 2024. 27 funds tracked by Wall St. Rank hold ALGS as of Q3 2024.

  • HighTower Advisors reported no remaining Aligos Therapeutics position as of Q3 2024 after selling out during the quarter.
  • HighTower Advisors sold 400 Aligos Therapeutics shares in Q3 2024, an estimated $4K.
  • HighTower Advisors first reported a position in Aligos Therapeutics in Q2 2024 and held it in 1 quarter.
  • HighTower Advisors's Aligos Therapeutics position peaked at $4K in Q2 2024.
  • 27 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q3 2024.

Based on HighTower Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.